$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti

$rmti Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-K Financial Statement

#000162828020003683 Filed on March 17, 2020

Income Statement

Concept	2018 Q4	2018	2017 Q4
Revenue	$16.85M	$63.39M	$14.84M
YoY Change	13.54%	10.63%	10.83%
Cost Of Revenue	$15.67M	$64.97M	$16.06M
YoY Change	-2.43%	21.22%	40.88%
Gross Profit	$1.180M	-$1.585M	-$1.220M
YoY Change	-196.72%	-142.83%	-161.31%
Gross Profit Margin	7.0%	-2.5%	-8.22%
Selling, General & Admin	$7.900M	$23.08M	$5.870M
YoY Change	34.58%	-0.93%	-2.98%
% of Gross Profit	669.49%
Research & Development	$2.710M	$5.600M	$2.130M
YoY Change	27.23%	-11.39%	77.5%
% of Gross Profit	229.66%
Depreciation & Amortization	$180.0K	$650.1K	$130.0K
YoY Change	38.46%	27.48%	-27.78%
% of Gross Profit	15.25%
Operating Expenses	$10.61M	$28.68M	$8.000M
YoY Change	32.63%	-3.17%	10.34%
Operating Profit	-$9.430M	-$32.44M	-$9.220M
YoY Change	2.28%	25.15%	75.29%
Interest Expense	$50.00K	$310.0K	$180.0K
YoY Change	-72.22%		-14.29%
% of Operating Profit
Other Income/Expense, Net		$313.3K
YoY Change
Pretax Income	-$9.380M	-$32.13M	-$9.040M
YoY Change	3.76%	23.96%	79.01%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.380M	-$32.13M	-$9.040M
YoY Change	3.76%	23.94%	79.01%
Net Earnings / Revenue	-55.67%	-50.68%	-60.92%
Basic Earnings Per Share
Diluted Earnings Per Share	-$163.3K	-$608.3K	-$176.3K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.53M	$33.53M	$33.06M
YoY Change	1.43%	1.42%	-42.94%
Cash & Equivalents	$22.71M	$22.71M	$8.407M
Short-Term Investments	$10.82M	$10.82M	$24.65M
Other Short-Term Assets	$1.900M	$1.900M	$1.780M
YoY Change	6.74%	6.74%	-12.32%
Inventory	$4.039M	$4.040M	$7.640M
Prepaid Expenses
Receivables	$6.980M	$6.980M	$6.360M
Other Receivables	$370.0K	$370.0K	$0.00
Total Short-Term Assets	$46.83M	$46.83M	$48.83M
YoY Change	-4.11%	-4.1%	-37.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.638M	$2.640M	$2.550M
YoY Change	3.46%	3.53%	83.45%
Goodwill	$900.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$536.5K	$2.170M	$6.480M
YoY Change	-91.72%	-66.51%	178.11%
Total Long-Term Assets	$5.733M	$5.730M	$9.950M
YoY Change	-42.39%	-42.41%	114.44%
TOTAL ASSETS
Total Short-Term Assets	$46.83M	$46.83M	$48.83M
Total Long-Term Assets	$5.733M	$5.730M	$9.950M
Total Assets	$52.56M	$52.56M	$58.78M
YoY Change	-10.59%	-10.58%	-29.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.492M	$4.490M	$4.220M
YoY Change	6.45%	6.4%	-27.99%
Accrued Expenses	$5.130M	$5.130M	$4.720M
YoY Change	8.68%	8.69%	12.11%
Deferred Revenue	$2.253M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.20M	$13.20M	$9.140M
YoY Change	44.47%	44.42%	-9.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.08M	$12.08M	$16.72M
YoY Change	-27.75%	-27.75%	-16.61%
Total Long-Term Liabilities	$12.08M	$12.08M	$16.72M
YoY Change	-27.75%	-27.75%	-16.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.20M	$13.20M	$9.140M
Total Long-Term Liabilities	$12.08M	$12.08M	$16.72M
Total Liabilities	$25.28M	$25.28M	$25.87M
YoY Change	-2.28%	-2.28%	-14.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$272.4M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.28M	$27.28M	$32.91M
YoY Change
Total Liabilities & Shareholders Equity	$52.56M	$52.56M	$58.78M
YoY Change	-10.59%	-10.58%	-29.31%

Cashflow Statement

Concept	2018 Q4	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$9.380M	-$32.13M	-$9.040M
YoY Change	3.76%	23.94%	79.01%
Depreciation, Depletion And Amortization	$180.0K	$650.1K	$130.0K
YoY Change	38.46%	27.48%	-27.78%
Cash From Operating Activities	-$5.780M	-$20.42M	-$4.810M
YoY Change	20.17%	-3.27%	-990.74%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	-$740.0K	-$970.0K
YoY Change	-84.54%	-55.95%	3133.33%
Acquisitions
YoY Change
Other Investing Activities	$2.360M	$13.47M	$10.30M
YoY Change	-77.09%	-16.8%	-493.13%
Cash From Investing Activities	$2.200M	$12.72M	$9.320M
YoY Change	-76.39%	-12.25%	-451.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	22.00M	$22.00M	10.00K
YoY Change	219900.0%	-1118.68%
NET CHANGE
Cash From Operating Activities	-5.780M	-$20.42M	-4.810M
Cash From Investing Activities	2.200M	$12.72M	9.320M
Cash From Financing Activities	22.00M	$22.00M	10.00K
Net Change In Cash	18.42M	$14.31M	4.520M
YoY Change	307.52%	-263.14%	-314.22%
FREE CASH FLOW
Cash From Operating Activities	-$5.780M	-$20.42M	-$4.810M
Capital Expenditures	-$150.0K	-$740.0K	-$970.0K
Free Cash Flow	-$5.630M	-$19.68M	-$3.840M
YoY Change	46.61%	1.29%	-773.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001041024
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69049102	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q2	dei	Entity Public Float EntityPublicFloat	152509967	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	ROCKWELL MEDICAL, INC.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018Q4	rmti	Aggregate Cash Compensation Paid To Directors AggregateCashCompensationPaidToDirectors	330000	USD
CY2019Q4	rmti	Aggregate Cash Compensation Paid To Directors AggregateCashCompensationPaidToDirectors	202500	USD
CY2019	rmti	Agreement Refund Trigger Event Repayment Percent Criteria AgreementRefundTriggerEventRepaymentPercentCriteria	0.25
CY2019Q4	us-gaap	Goodwill Goodwill	900000	USD
CY2019	rmti	Average Payment Term Of Customers AveragePaymentTermOfCustomers	P30D
CY2019	rmti	Average Payment Term Of Distributors AveragePaymentTermOfDistributors	P45D
CY2018	rmti	Bad Debt Expense BadDebtExpense	0	USD
CY2019	rmti	Bad Debt Expense BadDebtExpense	0	USD
CY2019Q4	rmti	Cash Collateral And Escrow Deposit Held By Insurance Carriers For Workers Compensation Insurance CashCollateralAndEscrowDepositHeldByInsuranceCarriersForWorkersCompensationInsurance	300000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6221139	USD
CY2019Q3	rmti	Common Stock Increasein Shares Authorized CommonStockIncreaseinSharesAuthorized	50000000	shares
CY2018	rmti	Cost Basis Of Available For Sale Securities Adjusted Due To Reclassification CostBasisOfAvailableForSaleSecuritiesAdjustedDueToReclassification	-20178127	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5864968	USD
CY2019	rmti	Cost Basis Of Available For Sale Securities Adjusted Due To Reclassification CostBasisOfAvailableForSaleSecuritiesAdjustedDueToReclassification	-41677994	USD
CY2018Q4	rmti	Current And Non Current Inventory CurrentAndNonCurrentInventory	5675778	USD
CY2019Q4	rmti	Research And Development Related Liabilities Current ResearchAndDevelopmentRelatedLiabilitiesCurrent	283407	USD
CY2018	rmti	Researchand Development Licenses Related Party ResearchandDevelopmentLicensesRelatedParty	850000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	63148	USD
CY2019Q4	rmti	Current And Non Current Inventory CurrentAndNonCurrentInventory	4087906	USD
CY2018Q4	rmti	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	63413000	USD
CY2018Q4	rmti	Increase Decrease In Inventory Reserves And Write Offs IncreaseDecreaseInInventoryReservesAndWriteOffs	8800000	USD
CY2019	rmti	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	1803048	USD
CY2019	rmti	Researchand Development Licenses Related Party ResearchandDevelopmentLicensesRelatedParty	0	USD
CY2018	rmti	Restricted Stock Tendered In Satisfaction Of Tax Liabilities RestrictedStockTenderedInSatisfactionOfTaxLiabilities	0	USD
CY2019Q1	rmti	Sales Agreement Threshold Sale Of Share SalesAgreementThresholdSaleOfShare	40000000	USD
CY2019Q4	rmti	Self Insurance Estimated Loss Reserves And Additional Future Claims SelfInsuranceEstimatedLossReservesAndAdditionalFutureClaims	195000	USD
CY2019	rmti	Self Insurance Overall Limit SelfInsuranceOverallLimit	663282	USD
CY2019Q4	rmti	Self Insurance Reserve Per Occurrence SelfInsuranceReservePerOccurrence	350000	USD
CY2019	rmti	Self Insurance Retention Amount SelfInsuranceRetentionAmount	1000000	USD
CY2018Q4	rmti	Number Of Additional Agreements NumberOfAdditionalAgreements	3	agreement
CY2019	rmti	Number Of Distribution And License Agreements NumberOfDistributionAndLicenseAgreements	2	agreement
CY2019Q4	rmti	Self Insurance Retention Limits In Excess Of Claims Paid And Accrued SelfInsuranceRetentionLimitsInExcessOfClaimsPaidAndAccrued	662000	USD
CY2018Q3	rmti	Settlement Payment Agreement Standstill Period SettlementPaymentAgreementStandstillPeriod	P5Y
CY2019Q4	rmti	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	70791000	USD
CY2019	rmti	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	1864538	USD
CY2019Q4	rmti	Operating Loss Carryforwards Subjectto Expiration OperatingLossCarryforwardsSubjecttoExpiration	169000000	USD
CY2018	rmti	Research And Development Licenses Included In Settlement Payable ResearchAndDevelopmentLicensesIncludedInSettlementPayable	0	USD
CY2019Q4	rmti	Working Capital Net WorkingCapitalNet	24500000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4492071	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4202725	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5129761	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3018424	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6979514	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4517732	USD
CY2018Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	5000	USD
CY2018	rmti	Repurchase Of Common Shares To Pay Employee Withholding Taxes RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes	0	USD
CY2019Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	61164	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	170334	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	181597	USD
CY2019	rmti	Repurchase Of Common Shares To Pay Employee Withholding Taxes RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes	-279347	USD
CY2019	rmti	Research And Development Licenses Included In Settlement Payable ResearchAndDevelopmentLicensesIncludedInSettlementPayable	763422	USD
CY2018Q4	rmti	Research And Development Related Liabilities Current ResearchAndDevelopmentRelatedLiabilitiesCurrent	86820	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	51980	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	299596257	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	326777250	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4387554	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4951777	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4387554	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4951820	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2104	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	8932	USD
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12624103	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12968474	shares
CY2018Q4	us-gaap	Assets Assets	52557784	USD
CY2019Q4	us-gaap	Assets Assets	44316452	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	46825230	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	36873837	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17415	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13321	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1192	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1306	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	10801836	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	30182	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	309000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	14238161	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	10818059	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	14300000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	14250176	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22713980	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11794526	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11800000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8406917	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22713980	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11794526	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14307063	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10919454	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.96
CY2018Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2770781	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57034154	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65378890	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57034154	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65378890	shares
CY2018Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	5703	USD
CY2019Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	6538	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32027327	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34139199	USD
CY2018	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	USD
CY2019	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	USD
CY2018Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	14329000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12076000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2252868	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2233640	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12076399	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9842762	USD
CY2018Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	63143	USD
CY2019Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	55100	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	64973157	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	58463859	USD
CY2018	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-222338	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	468000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6405000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63413000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3266000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7514000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2752000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63722000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70791000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52935000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71259000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1685000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	13000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	18000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	866000	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	426000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	280000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	6872000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	6872000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	45055000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	22000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	122000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	136000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	187000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	332000	USD
CY2019Q4	us-gaap	Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital	3800000	USD
CY2018	us-gaap	Depreciation Depreciation	649789	USD
CY2019	us-gaap	Depreciation Depreciation	787822	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	650142	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	788175	USD
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	850000	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	187849	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2279
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2279
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1525599	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1018196	USD
CY2019	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P17Y
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	10762	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	773	USD
CY2018	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2019	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2018	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-4752	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-4561	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22077720	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20997948	USD
CY2018Q4	us-gaap	Goodwill Goodwill	920745	USD
CY2018Q4	us-gaap	Goodwill Goodwill	900000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	920745	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Gross Profit GrossProfit	-1584540	USD
CY2019	us-gaap	Gross Profit GrossProfit	2838942	USD
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7299026	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7780323	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7299026	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7780323	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	269912	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1473648	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	623948	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2776789	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2394051	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2252865	USD
CY2018	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	416668	USD
CY2019	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-312668	USD
CY2018	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	371217	USD
CY2019	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	-371217	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	835641	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-316872	USD
CY2018	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	3432100	USD
CY2019	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	1975613	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	165712	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-933960	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	271889	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-532222	USD
CY2018Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	371217	USD
CY2019Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	0	USD
CY2018	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	535641	USD
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	367077	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1798101	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1432290	USD
CY2018	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	8784000	USD
CY2019	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	1271000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	4038778	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	3646906	USD
CY2018Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1637000	USD
CY2019Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	441000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3621548	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2471234	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	256129	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	184382	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21084876	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12723498	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4749782	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20419934	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27300000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27254548	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-32125858	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-34128031	USD
CY2018Q4	us-gaap	Notes Payable NotesPayable	0	USD
CY2019Q4	us-gaap	Notes Payable NotesPayable	763422	USD
CY2019	us-gaap	Lease Cost LeaseCost	2410451	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3590080	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1623260	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	97423	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	237410	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	587189	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1044798	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	316060	USD
CY2018Q4	us-gaap	Liabilities Liabilities	25280910	USD
CY2019Q4	us-gaap	Liabilities Liabilities	23996949	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52557784	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44316452	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13204511	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12373561	USD
CY2018Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	416668	USD
CY2019Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	104000	USD
CY2019Q3	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	3700000	USD
CY2018	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1030000	USD
CY2019	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	430000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22003499	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-32439161	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-34525290	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	2076037	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	2393825	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3274020	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1493394	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1780626	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	2014548	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3212530	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	232300000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3342008	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2973368	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	536516	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	434935	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	109293	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-10395	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-10762	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-773	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	109293	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-10395	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	313303	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	397259	USD
CY2018Q4	us-gaap	Other Receivables OtherReceivables	6980000	USD
CY2019Q4	us-gaap	Other Receivables OtherReceivables	4203000	USD
CY2018	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	250000	USD
CY2019	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	750000	USD
CY2018	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	744256	USD
CY2019	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	587452	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2019Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1903682	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2979504	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	33895481	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	38265664	USD
CY2018	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	400	USD
CY2019	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	67548	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	147900	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8859432	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8298373	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2638293	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2433405	USD
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	24900000	USD
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1145132	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5642317	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5600000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6886251	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6900000	USD
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1100000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-272388234	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306516265	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306500000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	63388617	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	4387554	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	63389000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	61303000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	61302801	USD
CY2018Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	14300000	USD
CY2019Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	12100000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5077068	USD
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1004584	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9050033	USD
CY2018	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	21935951	USD
CY2018Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21900000	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-279347	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	67548	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	147900	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	147900	USD
CY2018	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	759028	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	32913148	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	27276874	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20319503	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	317788	USD
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52824486	shares
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	4951777	USD
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.09
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.93
CY2018Q4	us-gaap	Share Price SharePrice	3.61
CY2018Q4	us-gaap	Share Price SharePrice	3.97
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	313600	shares
CY2018	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	210132	shares
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	16626	USD
CY2018Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5541562	shares
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	267500	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60918544	shares
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of our financial statements include estimates associated with revenue recognition, allowance for doubtful accounts, inventory reserves, accrued expenses, deferred license revenue, stock-based compensation, impairments of long‑lived assets, and accounting for income taxes.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-20-003683-index-headers.html	Edgar Link	pending
0001628280-20-003683-index.html	Edgar Link	pending
0001628280-20-003683.txt	Edgar Link	pending
0001628280-20-003683-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rmti-20191231.xml	Edgar Link	completed
rmti-20191231.xsd	Edgar Link	pending
rmti-20191231x10k.htm	Edgar Link	pending
rmti-20191231x10kxex311.htm	Edgar Link	pending
rmti-20191231x10kxex312.htm	Edgar Link	pending
rmti-20191231x10kxex321.htm	Edgar Link	pending
rmti-20191231x10kxex42.htm	Edgar Link	pending
rmti-20191231x10kxexhibitx.htm	Edgar Link	pending
rmti-20191231_cal.xml	Edgar Link	unprocessable
rmti-20191231_def.xml	Edgar Link	unprocessable
rmti-20191231_lab.xml	Edgar Link	unprocessable
rmti-20191231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti

2018 Q4 Form 10-K Financial Statement

#000162828020003683 Filed on March 17, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTI ROCKWELL MEDICAL, INC. Stock $rmti

2018 Q4 Form 10-K Financial Statement

#000162828020003683 Filed on March 17, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti